Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06984328 · ClinicalTrials.gov registry record · Phase 2
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
A Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), sponsored by Genmab.
- Active
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 2
- Study locations
NCT06984328: Active Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), sponsored by Genmab.
NCT06984328 is a Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) that is active but no longer recruiting, run by Genmab. The registered enrollment target is 1 participants, below the 367-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06984328, a Phase 2 study of Cutaneous Melanoma and Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), is active but no longer recruiting, sponsored by Genmab.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. All participants will receive active drugs; no one will be given a placebo. The trial duration will be approximately 15 months for each participant, including a 28-day screening period and estimated 4-month treatment and 10-month follow-up periods; however, the duration of the treatment and follow-up periods may vary for each participant. Participants will have regular check-ups while on treatment, with visits every week initially, and then every 3 weeks later in the trial.
Primary Outcome
Assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Acasunlimab
Study Locations (2)
Tennessee
- Tennessee Oncology, PLLC - Nashville
Other
- Pan American Center for Oncology Trials, LLC - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2029-07-15 |
| Phase | Phase 2 |
What the registry record for NCT06984328 still lists
NCT06984328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 367-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06984328 reports a single indexed study location in Tennessee, Other.
Frequently Asked Questions
What is clinical trial NCT06984328 about?
NCT06984328 is a clinical study titled "Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)". The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in participants with locally advanced or metastatic melanoma of the skin. ...
What is the current status of trial NCT06984328?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2025-07-25. Estimated completion is 2029-07-15.
What conditions does trial NCT06984328 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV).
What interventions are being tested in trial NCT06984328?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Acasunlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06984328?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06984328 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06984328's enrollment target sits among peer trials
1 31st of 30 the lowest of 30 other Cutaneous Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cutaneous Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
COMPLETED · Phase 2
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI